Advocacy - Intellectual Property

CLSA Letter of Support for STRONGER Patents Act – July 2019

July 12, 2019 

The Honorable Chris Coons
218 Russell Senate Building
Washington, D.C. 20510
The Honorable Tom Cotton
326 Russell Senate Office Building
Washington, D.C. 20515
The Honorable Steve Stivers
2234 Rayburn House Office Building
Washington, D.C. 20515
The Honorable Bill Foster
2366 Rayburn House Office Building
Washington, D.C. 20515

 Dear Senators Coons and Cotton and Representatives Stivers and Foster: 

On behalf of California Life Sciences Association (CLSA) – the statewide public policy and business leadership organization representing California’s leading life science innovators, including medical device, diagnostic, biotechnology and pharmaceutical companies, research universities and private, non‐profit institutes, and venture capital firms – I am writing to express our strong support for the Support Technology and Research for Our Nation’s Growth and Economic Resilience (STRONGER) Patents Act of 2019 (S.2082/H.R. 3666). We supported earlier versions of this legislation in the 114th and 115th Congresses, and appreciate your thoughtful approach to this revised legislation and continued efforts to curb abusive patent litigation practices while maintaining and strengthening important patent-holder rights and protections.  

As you know, life sciences research is extremely expensive and a companies’ ability to attract investment for developing the next generation of treatments, therapies, and technologies depends on a strong and reliable patent system. The biomedical sector in California consists of both relatively small, entrepreneurial, and venture capital-backed firms that have yet to bring products to market, and established pharmaceutical, biotech, and device companies with products on the market that enhance, improve, and save patient lives on a daily basis. For small and emerging companies especially, intellectual property is typically their most valuable and sometimes only asset. That is why patent rights, and the ability to legitimately enforce them against bona fide infringers, remain a top priority for California’s research universities, private research institutes, and biomedical companies large and small. They are also what incentivize companies to engage in the high-risk, high-cost R&D that makes the discovery, development, and commercialization of life-saving medicines and treatments possible.

Read More